or Try an Advanced Search...

    Disorders Stocks List

    Symbol Grade Name % Change
    IONS B Ionis Pharmaceuticals, Inc. 1.02
    REGN B Regeneron Pharmaceuticals, Inc. -1.97
    CORT C Corcept Therapeutics Incorporated -3.36
    OMER C Omeros Corporation 0.78
    NBIX C Neurocrine Biosciences, Inc. 0.54
    ITCI C Intra-Cellular Therapies Inc. 0.77
    XGN C Exagen Inc. 1.69
    PHAT C Phathom Pharmaceuticals, Inc. 0.00
    CPRX D Catalyst Pharmaceutical Partners, Inc. -3.10
    ONCO D Onconetix, Inc. -7.58
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Medical Care Facilities Medical Instruments & Supplies
    Related Stock Lists: Biopharmaceutical Medicine Disease Health Sciences Chronic Condition Genodermatoses Organ Systems Syndromes Age Related Diseases Alpha 1 Antitrypsin Anemia Anticonvulsants Antidepressants Antitrypsin Deficiency Appetite Stimulants Autism Spectrum Disorder Autoimmune Disease Autoimmunity Biosurgery Products Bone

    Related ETFs - A few ETFs which own one or more of the above listed Disorders stocks.

    Symbol Grade Name Weight
    PBE B PowerShares Dynamic Biotech & Genome 10.82
    IBRN D iShares Neuroscience and Healthcare ETF 7.98
    FBT B First Trust Amex Biotech Index Fund 6.55
    BBP B BioShares Biotechnology Products Fund 5.05
    ARKG F ARK Genomic Revolution Multi-Sector ETF 4.95
    View all Disorders ETFs...
    Compare ETFs
    Compare IBRN to FBT Compare PBE to BBP Compare PBE to IBRN

        Disorders Stocks Recent News

        Date Stock Title
        Jul 3 REGN Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
        Jul 3 REGN Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
        Jul 3 REGN Sanofi, Regeneron win EU label expansion for Dupixent in COPD
        Jul 3 REGN Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
        Jul 2 REGN Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
        Jul 2 REGN Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
        Jul 2 NBIX FDA grants priority review for Neurocrine’s crinecerfont NDAs
        Jul 1 NBIX FDA sets target action dates for Neurocrine drug applications
        Jul 1 REGN Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
        Jul 1 NBIX Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
        Jun 28 NBIX How Medicare drug price negotiations could hit pharma stocks
        Jun 28 REGN What's Going On With Regeneron Pharmaceuticals Stock On Friday?
        Jun 28 REGN Regeneron lymphoma antibody drug endorsed for conditional approval in EU
        Jun 28 REGN Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
        Jun 27 REGN Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
        Jun 27 REGN 3 Biotech Stocks That Could Make Your Grandchildren Rich
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Medical Care Facilities Medical Instruments & Supplies
        Related Stock Lists: Biopharmaceutical Medicine Organ Systems Schizophrenia Alcohol Bipolar Disorder Cognitive Disorders Diabetes Epilepsy Genodermatoses Insomnia Mental Health Movement Disorders Neurological Disorders Pharmaceutical Prostate Cancer Psychiatric Diagnosis Psychiatry Rare Diseases Surgery
        Disorders

        Disorder may refer to randomness, non-order, or no intelligible pattern. Disorder may also refer to:

        More about Disorders
        Browse All Tags